FSGS: New Guidelines and Emerging Treatments to Reduce Proteinuria to Goals and Slow Decline in Kidney Function

Target Audience
The intended audience for this activity are nephrologists. The secondary audiences are primary care/internal medicine physicians.

Learning Objectives
At the conclusion of this activity, participants will be able to:

FSGS: New Guidelines and Emerging Treatments to Reduce Proteinuria to Goals and Slow Decline in Kidney Function

Describe the disease burden experienced by children and adults with FSGS, including the consequences of late diagnoses and the limitations of current therapies
Define the pathophysiology of FSGS, specifically as it relates to the role of ET-1 and RAAS on proteinuria regulation
Explain the mechanism of action and efficacy and safety data for emerging dual AT1/ETA blockers, and describe how these agents may help patients with primary or genetic FSGS reach the clinically meaningful outcome of partial proteinuria reduction and rate of eGFR slope decline
Apply updated KDIGO guidelines for the diagnosis and prognosis of FSGS, differentiating primary, secondary, and genetic FSGS